Brian G. Feagan

1.2k total citations
12 papers, 753 citations indexed

About

Brian G. Feagan is a scholar working on Genetics, Epidemiology and Economics and Econometrics. According to data from OpenAlex, Brian G. Feagan has authored 12 papers receiving a total of 753 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 5 papers in Epidemiology and 4 papers in Economics and Econometrics. Recurrent topics in Brian G. Feagan's work include Inflammatory Bowel Disease (10 papers), Microscopic Colitis (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Brian G. Feagan is often cited by papers focused on Inflammatory Bowel Disease (10 papers), Microscopic Colitis (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Brian G. Feagan collaborates with scholars based in United States, Canada and Germany. Brian G. Feagan's co-authors include William J. Sandborn, Mohan Bala, Leanne R. Larson, Marc D. Silverstein, William S. Harmsen, Edward V. Loftus, Alan R. Zinsmeister, William J. Tremaine, Paul J. Nietert and C J Hawkey and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Brian G. Feagan

10 papers receiving 729 citations

Peers

Countries citing papers authored by Brian G. Feagan

Since Specialization

Citations

This map shows the geographic impact of Brian G. Feagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian G. Feagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian G. Feagan more than expected).

Fields of papers citing papers by Brian G. Feagan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian G. Feagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian G. Feagan. The network helps show where Brian G. Feagan may publish in the future.

Co-authorship network of co-authors of Brian G. Feagan

This figure shows the co-authorship network connecting the top 25 collaborators of Brian G. Feagan. A scholar is included among the top collaborators of Brian G. Feagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian G. Feagan. Brian G. Feagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial 2025 ·The Lancet. Gastroenterology & hepatology ·Vipul Jairath, (unknown), Geert D’Haens, Brian G. Feagan, Laurent Peyrin-Biroulet, (unknown), Ingrid C. Gaemers, (unknown), Allyson Terry, Kevin J. Roberts, (unknown), Pamela Wedel, Jacqueline Benson, Carlos Sattler	0
2	744: LONG-TERM EFFICACY AND SAFETY OF INTRAVENOUS TULISOKIBART IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE OPEN-LABEL EXTENSION PERIOD OF THE PHASE 2 ARTEMIS-UC STUDY 2025 ·Gastroenterology ·Christopher Ma, (unknown), Miles Sparrow, (unknown), Mark Yen, (unknown), Brian G. Feagan, Bruce E. Sands	0
3	Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease 2024 ·SHILAP Revista de lepidopterología ·Brian G. Feagan, Remo Panaccione, (unknown), Edward V. Loftus, Laurent Peyrin-Biroulet, Takehiro Arai, Wan‐Ju Lee, Jenny Griffith, Jasmina Kalabic, Kristina Kligys, (unknown), Xiaomei Liao, (unknown)	2
4	Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn’s Disease 2024 ·SHILAP Revista de lepidopterología ·Brian G. Feagan, Jean–Frédéric Colombel, Remo Panaccione, (unknown), (unknown), Koji Kamikozuru, Christopher Ma, Wan‐Ju Lee, Jenny Griffith, Namita Joshi, Kristina Kligys, Jasmina Kalabic, (unknown), Marla Dubinsky	1
5	Management of Small Bowel Crohn’s Disease Strictures: To Cut, to Stretch, or to Treat Inflammation? 2024 ·Gastroenterology ·Cathy Lu, Brian G. Feagan, Joel G. Fletcher, Mark E. Baker, Stefan D. Holubar, Florian Rieder	1
6	S1370 Single Ascending Dose Results From a Phase 1 Clinical Trial of BT-600, a Combination Product of the NaviCap Targeted Oral Delivery Platform and Tofacitinib 2024 ·The American Journal of Gastroenterology ·Brian G. Feagan, (unknown), (unknown), (unknown), (unknown), Paul Shabram, (unknown), (unknown)	1
7	Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study 2024 ·Alimentary Pharmacology & Therapeutics ·Brian G. Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Silvio Danese, Edward V. Loftus, Ian Beales, Stefan Schreiber, Hyo Jong Kim, (unknown), (unknown), (unknown), Christine Rudolph, Laurent Peyrin‐Biroulet	4
8	P-104 SECURE 2016 ·Inflammatory Bowel Diseases ·Scott Lee, (unknown), Brian G. Feagan, Gary R. Lichtenstein, Elizabeth Andrews, (unknown), Faten Aberra, Humberto Aguilar, (unknown), Gordana Kosutic, (unknown), Amanda Golembesky, (unknown), (unknown), Edward V. Loftus	1
9	Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3 2014 ·The American Journal of Gastroenterology ·Jean–Frédéric Colombel, William J. Sandborn, Subrata Ghosh, Douglas C. Wolf, Remo Panaccione, Brian G. Feagan, Walter Reinisch, Anne Robinson, Andreas Lazar, Martina Kron, Bidan Huang, Martha Skup, Roopal Thakkar	124
10	An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial 2001 ·Gastroenterology ·William J. Sandborn, Brian G. Feagan, S. B. Hanauer, D. H. Present, Lloyd R. Sutherland, Michael A. Kamm, Douglas C. Wolf, Jeffrey P. Baker, C J Hawkey, André Archambault, Çharles N. Bernstein, (unknown), Patricia K. Heath, (unknown)	197
11	Annual cost of care for Crohn's disease: a payor perspective 2000 ·The American Journal of Gastroenterology ·Brian G. Feagan, (unknown), Leanne R. Larson, Mohan Bala	153
12	Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort 1999 ·Gastroenterology ·Marc D. Silverstein, Edward V. Loftus, William J. Sandborn, William J. Tremaine, Brian G. Feagan, Paul J. Nietert, William S. Harmsen, Alan R. Zinsmeister	269

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact